Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
COVID-19
About this trial
This is an interventional treatment trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
- Conscious consent to participate in the study
- Patients 18 to 75 years of age with COVID-19 who have been diagnosed with PCR.
- Strong clinical suspicion of covid 19 with positive findings in CT Scan
- Shortness of breath
Exclusion Criteria:
- Patients with HIV
- Patients with cancer undergoing chemotherapy
- Patients receiving Immune Mediators
- Patients need hospitalization in the intensive care unit
- Patients with uncontrolled heart, kidney or liver failure
- Pregnant or lactating women
- Intolerance to the drugs used in this study (symptoms such as diarrhea, nausea, vomiting and respiratory problems)
Sites / Locations
- Mohammad Sadegh Bagheri BaghdashtRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Test Group
Control Group
Intervention group: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days / PHR160 spray one hour oral puff with Demyar ten times a day for ten days in a row, for ten days.
Control group: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days Daily / 25 mg prednisolone daily for 5 days / placebo spray one hourly oral puff ten times a day for ten days in a row, for ten days